Biogen Inc. (Nasdaq: BIIB) Q2 2026 earnings call, held on July 29, 2026, centered on five imminent registrational readouts across lupus, antibody-mediated rejection, and Dravet syndrome, while the FDA approval of a subcutaneous initiation formulation for lecanemab reshaped the Alzheimer's competitive picture. Management also signaled a pause on its BTK inhibitor program despite proof-of-concept data, and positioned its anti-tau asset as a long-term option rather than a near-term growth driver.
Total revenue for Q2 2026 was USD 2.7 billion, up 3% year-over-year, with core pharmaceutical revenue of USD 1.8 billion, up 4% year-over-year; Biogen raised full-year revenue guidance from a mid-single-digit percentage decrease to a mid-single-digit percentage increase, incorporating the Apellis acquisition.
Lecanemab SC approval reshapes Alzheimer's access dynamics
The FDA approved Leqembi Iqlik (lecanemab-irmb subcutaneous) for induction dosing earlier in July 2026, completing a fully subcutaneous pathway for both initiation and maintenance of lecanemab (Leqembi) treatment in early Alzheimer's disease. The product is expected to be available in market by end of August 2026.
Biogen and Eisai also presented real-world data from the LEADER study at the Alzheimer's Association International Conference (AAIC) in July 2026, reporting that over 75% of early Alzheimer's patients enrolled in the study remained stable and nearly 7% improved over an average of 17 months of continuous treatment.
Management said subcutaneous induction could expand eligibility among patients unable or unwilling to attend infusion centers, improve persistence and reduce Kisunla’s once-monthly dosing advantage. Medicare Part D coverage will become clearer at the beginning of 2027.
Litifilimab / TOPAZ-1 and TOPAZ-2 (SLE): Q4 2026 data imminent
Litifilimab, Biogen's anti-BDCA2 (blood dendritic cell antigen 2) monoclonal antibody, is approaching key readouts. Data from both Phase III TOPAZ-1 and TOPAZ-2 trials in systemic lupus erythematosus (SLE) are expected in Q4 2026. Singhal said the Phase III program incorporates lessons from prior lupus trials through tighter control of placebo responses, corticosteroid use and patient selection based on the Phase II LILAC study. The primary endpoint is SRI-4, with BICLA as a key secondary endpoint. Management declined to quantify the placebo separation required for commercial differentiation, instead emphasizing litifilimab's broader effects on interferon signaling, chemokines and cytokines.
Commercially, Biogen cited a substantial unmet need in both SLE and cutaneous lupus erythematosus (CLE), noting that fewer than 5% of CLE patients currently receive an advanced therapy. CEO Christopher Viehbacher described lupus as a potential USD 8 billion addressable market, with CLE representing an additional opportunity where no approved therapy currently exists.
Litifilimab / AMETHYST (CLE) and felzartamab / TRANSCEND (AMR): Both accelerated to H1 2027
Biogen disclosed that Phase III readouts for both litifilimab in CLE and felzartamab in antibody-mediated rejection (AMR) have been pulled forward to the first half of 2027, citing strong enrollment momentum.
For litifilimab in CLE, Biogen will first present 52-week Phase II data from the ongoing AMETHYST study at the European Academy of Dermatology and Venereology (EADV) Annual Conference this autumn, which management said would provide insight into durability of response before the Phase III portion reads out. Singhal said she regarded CLE and SLE as having comparable probabilities of success, not a higher bar for either.
For felzartamab in AMR, the TRANSCEND trial is a placebo-controlled, biopsy-driven study. Viehbacher cited Phase II open-label data showing 80% resolution of AMR in a small study and noted that approximately 11,000 patients in the US alone have AMR, with no approved therapy currently available. He referenced Otsuka's pricing for IgA nephropathy (IgAN) as a comparable benchmark, suggesting an addressable market of USD 3 billion to USD 4 billion. A separate Phase III trial, TRANSPIRE, evaluating felzartamab in microvascular inflammation (MVI) — a donor-specific antibody-negative population of approximately 6,000 US patients — is already under way, with data expected to emerge subsequently. Of note, Biogen paid USD 100 million upfront to TJ Bio in Q2 to acquire worldwide rights to felzartamab, having previously held rights outside China.
Salanersen: Phase III initiated
Biogen initiated the Phase III STELLAR-1 study of salanersen in SMA, triggering a USD 45 million milestone to Ionis Pharmaceuticals, and reported that the asset had received Breakthrough Therapy designation. Management positioned salanersen as the longer-term successor to Spinraza high dose, which generated Q2 revenue of USD 402 million, up 2%.
BIIB091 (BTK inhibitor): Proof of concept achieved
Analysts pressed Biogen on the fate of BIIB091, its peripheral, non-covalent BTK inhibitor, after Phase II proof-of-concept data in relapsing-remitting multiple sclerosis (RRMS). Singhal said the trial achieved proof of concept and indicated potentially compelling efficacy in RRMS, but said the company was pausing to assess next steps given the competitive landscape and "external inflections" in the BTK inhibitor field amid competitive developments and safety concerns affecting the broader BTK inhibitor class.
Diranersen: Signal confirmed, Phase III details remain open
Analysts asked about feedback from the neurology and regulatory communities following the presentation of full Phase II CELIA data for diranersen, Biogen's anti-tau antisense oligonucleotide, at AAIC in July 2026. Viehbacher said reviews by an independent biostatistician, an external expert and multiple advisory groups supported management’s view that the signal was real and unlikely to be due to chance. He said FDA consultations and long-term extension data would inform Phase III design, but was explicit that diranersen would not affect Biogen's growth this decade. Management is also internally evaluating potential combination strategies, including pairing an anti-tau agent with an anti-amyloid antibody, though no decisions have been made.
Forward-Looking Catalysts
- Litifilimab SLE (TOPAZ-1 and TOPAZ-2), Q4 2026: Dual Phase III readouts represent Biogen's most proximate binary event. Positive Phase III data would support Biogen's first regulatory filing in SLE.
- Felzartamab AMR (TRANSCEND), H1 2027: Phase III data in a disease with no approved therapy and approximately 11,000 US patients. Biogen's acquisition of worldwide rights to felzartamab in Q2 2026 and the accelerated readout timeline indicate high internal conviction; positive data would establish a new commercial franchise in nephrology transplant.
- Zorevunersen Dravet syndrome (EMPEROR), within the next four quarters: Enrollment in the Phase III EMPEROR study completed in June 2026 with 162 patients. Biogen holds ex-US rights to zorevunersen from its partnership with Stoke Therapeutics (Nasdaq: STOK), with management citing at least 7,000 patients in Europe alone and a USD 2 billion ex-US addressable opportunity across key Biogen territories.
Access the AllSci platform to explore the science behind the news.
Spot something wrong? Report an issue with this article
